Kim Ann Dang, MD
Hospice and Palliative Medicine · la Mesa, CANPI 1760872188
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 112 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 14.7% — the pattern of someone who eats at a lot of different presentations. Among hospice and palliative medicine clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 112 payments — averaging $21.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$361
- Lilly USA, LLC$283
- Novo Nordisk$266
- Pfizer$244
- Johnson & Johnson$129
- Novartis$106
- plus $1K from 21 others
What the payments were for
- Food & beverage$2,455100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 17 | $361 |
| Lilly USA, LLC | 14 | $283 |
| Novo Nordisk | 15 | $266 |
| Pfizer | 11 | $244 |
| Johnson & Johnson | 4 | $129 |
| Novartis | 5 | $106 |
| AstraZeneca | 5 | $102 |
| Viiv Healthcare Company | 4 | $98 |
| Radius Health, Inc. | 4 | $92 |
| Gilead | 3 | $89 |
| Amgen | 3 | $82 |
| Boston Scientific | 4 | $80 |
| Hologic Sales And Service, LLC | 2 | $77 |
| GSK | 3 | $64 |
| Teva Pharmaceuticals USA, Inc. | 3 | $61 |
| Daiichi Sankyo Inc. | 2 | $51 |
| Exact Sciences | 2 | $39 |
| Nevro Corp. | 1 | $33 |
| Boehringer Ingelheim | 2 | $32 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $28 |
| Astellas Pharma US Inc | 1 | $25 |
| Si-bone, Inc. | 1 | $25 |
| Halozyme Inc | 1 | $21 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $20 |
| Edwards Lifesciences | 1 | $16 |
| Merck | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
How this compares
$2,455 in reported general payments places this provider in the 90th percentile of 195 hospice and palliative medicine providers in California.
See all hospice and palliative medicine providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 13 | $90,776 |
| EliquisApixaban | 47 | $47,327 |
| OzempicSemaglutide | 44 | $39,763 |
| JardianceEmpagliflozin | 33 | $37,377 |
| RybelsusSemaglutide | 26 | $35,744 |
| TrulicityDulaglutide | 17 | $17,936 |
| EntrestoSacubitril/Valsartan | 17 | $15,494 |
| XareltoRivaroxaban | 12 | $13,479 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 16 | $13,443 |
| Breo ElliptaFluticasone/Vilanterol | 17 | $9,407 |
| Advair HfaFluticasone Propion/Salmeterol | 25 | $8,906 |
| Tresiba Flextouch U-100Insulin Degludec | 12 | $5,826 |
| Gabapentin | 79 | $2,297 |
| Atorvastatin Calcium | 155 | $1,534 |
| Wixela InhubFluticasone Propion/Salmeterol | 12 | $1,464 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $266 | $75,50670 claims |
| PfizerEliquis | $244 | $47,32747 claims |
| Boehringer IngelheimJardiance | $32 | $37,37733 claims |
| Lilly USA, LLCTrulicity | $283 | $17,93617 claims |
| NovartisEntresto | $106 | $15,49417 claims |
| Johnson & JohnsonXarelto | $129 | $13,47912 claims |
| GSKBreo Ellipta | $64 | $9,40717 claims |
| AbbVieSynthroid | $361 | $88815 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 195 hospice and palliative medicine providers in California.
Other hospice and palliative medicine in la Mesa
- Nicki Vithalanila Mesa$587
- Sharon YeeArcadia$44K
- Neil SoniFountain Valley$28K
- Marietta Abalos-GalitoSan Jose$21K
- Humayon KhanSanta Ana$7K
- Sorin BugaDuarte$5K
- Glenn CarrFresno$5K
- Steven HarrisFoster City$5K
- Christopher PhillipsMurrieta$4K
- William DaleDuarte$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.